Curriculum vitae Thomas Felzmann - ACTIVARTIS Biotech GmbH

Curriculum vitae Thomas Felzmann
Dr. Thomas Felzmann, MBA
Geschäftsführer Activartis Biotech GmbH, Privatdozent für Immunologie, Medizinische Universität
Wien
geboren 15. November 1960, verheiratet, zwei Kinder
Berufliche Laufbahn
seit 2003 Gründer und Geschäftsführer Activartis Biotech GmbH (vorm. Trimed
Biotech GmbH)
seit 1995 Direktor des Labors für Tumorimmunologie, St. Anna Kinderkrebsforschung,
Wien
1995-1998 Klinische Ausbildung in der pädiatrischen Onkologie, St. Anna
Kinderspital, Wien
1992-1995 Research Fellow am Human Genome Research Institute der National
Institutes of Health (NIH), USA
1991-1992 Forschungsassistent am Institut für Immunologie, Medizinische
Universität Wien
1987-1989 Arzt an der Blutbank des Österreichischen Roten Kreuzes, Wien
1987 Sozialarbeiter als Rettungsarzt, Österreichisches Rotes Kreuz, Wien
Ausbildung
2009 Hochschullehrgang für Pharmazeutisches Qualitätsmanagement
(Sachkundige Person, §7 AMBO 2009), Universität Wien
2007 Privatdozent für Immunologie, Medizinische Universität Wien
2003-2005 Executive MBA Programm an der Donauuniversität Krems, Abschluss als
Master of Business Administration, November 2005
1999 Facharzt für Klinische Immunologie
1980-1987 Medizinische Universität Wien, Abschluss als Doktor der Medizin,
Dezember 1987
1975-1980 HTL für Biochemie und Biochemische Technologie, Wien, Abschluss Juni
1980
Patente
2007 Immunmodulierende Dendritische Zellen, WO2009074341A1
2005 Methoden und Mittel für Diagnose und Behandlung von Leukämien
AT2051/2005
2003 Zelluläres Immuntherapeutikum, US05994126
Activartis Biotech GmbH Zimmermannplatz 10; 1090 Vienna, Austria;
Phone: +43 1 40170-4080; E-Mail: office@activartis.com; www.activartis.com
Firmenbuchnummer FN 242030 b; Handelsgericht Wien UID: ATU 57853601
Bank Austria Creditanstalt BLZ 12000; Konto-Nr: 51842230901; IBAN: AT061200051842230901; BIC: BKAUATWW

Bibliographie
1. Traxlmayr, M. W., D. Wesch, A. M. Dohnal, P. Funovics, M. B. Fischer, D. Kabelitz, and
T. Felzmann. 2010. Immune suppression by gammadelta T-cells as a potential regulatory
mechanism after cancer vaccination with IL-12 secreting dendritic cells. J Immunother 33:40-
52.
2. Simma, O., E. Zebedin, N. Neugebauer, C. Schellack, A. Pilz, S. Chang-Rodriguez, K. Lingnau,
E. Weisz, E. M. Putz, W. F. Pickl, T. Felzmann, M. Muller, T. Decker, V. Sexl, and D. Stoiber.
2009. Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor
surveillance. Cancer Res 69:203-211.
3. Jurgens, B., U. Hainz, D. Fuchs, T. Felzmann, and A. Heitger. 2009. Interferon-gammatriggered
indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic
cells induces regulatory activity in allogeneic T cells. Blood 114:3235-3243.
4. Dohnal, A. M., R. Luger, P. Paul, D. Fuchs, and T. Felzmann. 2009. CD40 ligation restores type 1
polarizing capacity in TLR4-activated dendritic cells that have ceased interleukin-12
expression. J Cell Mol Med 13:1741-1750.
5. Dohnal, A. M., S. Graffi, V. Witt, C. Eichstill, D. Wagner, S. Ul-Haq, D. Wimmer, and
T. Felzmann. 2009. Comparative evaluation of techniques for the manufacturing of dendritic
cell-based cancer vaccines. J Cell Mol Med 13:125-135.
6. Dohnal, A. M., V. Witt, H. Hugel, W. Holter, H. Gadner, and T. Felzmann. 2007. Phase I study of
tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer.
Cytotherapy 9:755-770.
7. Wimpissinger, T. F., T. Felzmann, H. Hügel, P. Funovics, and W. Stackl. 2006. Treatment of
advanced renal cell carcinoma with tumor lysate pulsed IL-12 secreting autologous dendritic
cells. J Clin Oncol 24:14585.
8. Dohnal, A. M., A. Inthal, T. Felzmann, S. Glatt, W. Sommergruber, G. Mann, H. Gadner, and
E. R. Panzer-Grumayer. 2006. Leukemia-associated antigenic isoforms induce a specific
immune response in children with T-ALL. Int J Cancer 119:2870-2877.
9. Hüttner, K. G., S. K. Breuer, P. Paul, O. Majdic, A. Heitger, and T. Felzmann. 2005. Generation
of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells. Cancer
Immunol Immunother 54:67-77.
10. Felzmann, T., K. G. Huttner, S. K. Breuer, D. Wimmer, G. Ressmann, D. Wagner, P. Paul,
M. Lehner, A. Heitger, and W. Holter. 2005. Semi-mature IL-12 secreting dendritic cells
present exogenous antigen to trigger cytolytic immune responses. Cancer Immunol
Immunother 54:769-780.
11. Lehner, M., J. Stockl, O. Majdic, W. Knapp, K. Huttner, T. Felzmann, and W. Holter. 2003. MHC
class II antigen signaling induces homotypic and heterotypic cluster formation of human
mature monocyte derived dendritic cells in the absence of cell death. Hum Immunol 64:762-
770.
12. Felzmann, T., V. Witt, D. Wimmer, G. Ressmann, D. Wagner, P. Paul, K. Huttner, and
G. Fritsch. 2003. Monocyte enrichment from leukapharesis products for the generation of
DCs by plastic adherence, or by positive or negative selection. Cytotherapy 5:391-398.
13. Felzmann, T., H. Gadner, and W. Holter. 2002. Dendritic cells as adjuvants in antitumor
immune therapy. Onkologie 25:456-464.
14. Felzmann, T. 2002. Use of dendritic cells (DCs) expressing interleukin 12 (IL-12). Austria.
15. Lehner, M., T. Felzmann, K. Clodi, and W. Holter. 2001. Type I interferons in combination with
bacterial stimuli induce apoptosis of monocyte-derived dendritic cells. Blood 98:736-742.
16. Lehner, M., T. Felzmann, K. Clodi, and K. Holter. 2001. Type I interferons in combination with
bacterial stimuli induce apoptosis of monocyte-derived dendritic cells. Blood 98:736-742.

17. Felzmann, T., M. Buchberger, M. Lehner, D. Printz, R. Kircheis, E. Wagner, H. Gadner, and
W. Holter. 2001. Functional maturation of dendritic cells by exposure to CD40L transgenic
tumor cells, fibroblasts or keratinocytes. Cancer Letters 168:145-154.
18. Felzmann, T., M. Buchberger, M. Jechlinger, R. Kircheis, E. Wagner, and H. Gadner. 2000.
Xenogenization by tetanus toxoid loading into lymphoblastoid cell lines and primary human
tumor cells mediated by polycations and liposomes. Cancer Lett 161:241-250.
19. Felzmann, T., W. J. Ramsey, and R. M. Blaese. 1999. Anti-tumor immunity generated by tumor
cells engineered to express B7-1 via retroviral or adenoviral gene transfer. Cancer Lett 135:1-10.
20. Kircheis, R., A. Kichler, G. Wallner, M. Kursa, M. Ogris, T. Felzmann, M. Buchberger, and
E. Wagner. 1997. Coupling of cell-binding ligands to polyethylenimine for targeted gene
delivery. Gene Therapy 4:409-418.
21. Felzmann, T., W. J. Ramsey, and R. M. Blaese. 1997. Characterization of the antitumor immune
response generated by treatment of murine tumors with recombinant adenoviruses
expressing HSVtk, IL-2, IL-6 or B7-1. Gene Ther 4:1322-1329.
22. Kuttesch, J. F., D. M. Parham, X. Luo, W. H. Meyer, L. Bowman, D. N. Shapiro, A. S. Pappo,
W. M. Crist, W. T. Beck, and P. J. Houghton. 1996. P-glycoprotein expression at diagnosis may
not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin
Oncol 14:886-900.
23. Felzmann, T., H. Gisslinger, and H. Ludwig. 1994. Immunological findings in patients with
myelodysplastic syndrome. Leuk Lymphoma 15:201-208.
24. Felzmann, T., H. Gisslinger, O. Krieger, O. Majdic, H. Ludwig, and U. Koller. 1993.
Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic
syndrome. Br J Haematol 84:428-435.
25. Szekeres, T., M. Fritzer, K. Pillwein, T. Felzmann, and P. Chiba. 1992. Cell cycle dependent
regulation of IMP dehydrogenase activity and effect of tiazofurin. Life Sci 51:1309-1315.
26. Maurer, D., T. Felzmann, W. Holter, P. Petera, J. Smolen, and W. Knapp. 1992. Evidence for the
presence of activated CD4 T cells with naive phenotype in the peripheral blood of patients
with rheumatoid arthritis. Clin Exp Immunol 87:429-434.
27. Gadd, S. J., T. Felzmann, O. Majdic, D. Maurer, P. Petera, W. J. Chen, J. Smolen, and W. Knapp.
1992. Phenotypic analysis of functionally associated molecules on peripheral blood and
synovial fluid monocytes from arthritis patients. Rheumatol Int 12:153-157.
28. Maurer, D., G. F. Fischer, T. Felzmann, O. Majdic, E. Gschwantler, W. Hinterberger, A. Wagner,
and W. Knapp. 1991. Ratio of complement receptor over Fc-receptor III expression: a sensitive
parameter to monitor granulocyte-macrophage colony-stimulating factor effects on
neutrophils. Ann Hematol 62:135-140.
29. Felzmann, T., S. Gadd, O. Majdic, D. Maurer, P. Petera, J. Smolen, and W. Knapp. 1991. Analysis
of function-associated receptor molecules on peripheral blood and synovial fluid granulocytes
from patients with rheumatoid and reactive arthritis. J Clin Immunol 11:205-212.
30. Maurer, D., T. Felzmann, and W. Knapp. 1990. A single laser flow cytometry method to
evaluate the binding of three antibodies. J Immunol Methods 135:43-47.